newsfilter
← Latest News
GlobeNewswire·

Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026

Quality of life remained stable during neoadjuvant treatment with efti, pembrolizumab and radiotherapy, with statistically significant improvement after surgery SYDNEY, AUSTRALIA, Oct. 23, 2026 (GLOBE NEWSWIRE) --